The use of the VerifyNow system to monitor antiplatelet therapy: A review of the current evidence

Platelets

Volumn 19, Issue 7, 2008, Pages 479-488

  Van Werkum, J W ^a   Harmsze, A M ^a   Elsenberg, E H A M ^a   Bouman, H J ^a   Ten Berg, J M ^a   Hackeng, C M ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Aspirin; Clopidogrel; Platelets; VerifyNow

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR;

ACUTE CORONARY SYNDROME; ASSAY; BLOOD CLOTTING PARAMETERS; CORONARY STENT; DRUG MONITORING; DRUG RESPONSE; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ACUTE CORONARY SYNDROME; DRUG MONITORING; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS;

EID: 55349114710     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100802317918     Document Type: Review

References (51)

1. Steinhubl SR, Berger PB, Mann JT III et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420.
2. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-533.
3. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-2383.
4. Savi P, Pereillo JM, Uzabiaga MF et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-896.
5. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006;46:277-300.
6. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251.
7. Gurbel PA, Bliden KP, Guyer K et al. Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820-1826.
8. Cuisset T, Frere C, Quilici J et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006;48:1339-1345.
9. Buonamici P, Marcucci R, Migliorini A et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-2317.
10. Matetzky S, Shenkman B, Guetta V et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
11. van Werkum JW, Hackeng CM, Smit AC, van't Hof AW, Verheugt F, Ten Berg JM. Monitoring antiplatelet therapy with point-of-care platelet function assays: A review of the evidence. Future Cardiology 2008;8:33-55.
12. Topol EJ, Ferguson JJ, Weisman HF et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997;278:479-484.
13. Montalescot G, Barragan P, Wittenberg O et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
14. Casterella PJ, Kereiakes DJ, Steinhubl SR et al. The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable. Catheter Cardiovasc Interv 2001;54:497-504.
15. Danzi GB, Capuano C, Sesana M, Mauri L, Sozzi FB. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention. Am J Cardiol 2006;97:489-493.
16. Kini AS, Richard M, Suleman J et al. Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). Am J Cardiol 2002;90:526-529.
17. Mammen EF, Comp PC, Gosselin R et al. PFA-100 system: A new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202.
18. Savion N, Varon D. Impact-the cone and plate(let) analyzer: Testing platelet function and anti-platelet drug response. Pathophysiol Haemost Thromb 2006;35:83-88.
19. Helena Laboratories. 2008. Ref Type: Internet Communication.
20. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005;46:1705-1709.
21. Steinhubl SR, Kereiakes DJ. In: Platelets. Michaelson AD, editor. Ultegra Rapid Platelet Function Analyzer, New York, CA: Academic Press/Elsevier Science; 2002.
22. Accumetrics Inc. VerifyNow-ASA (IIb/IIIa assay) package insert. San Diego, CA. 2007. (Pamphlet).
23. Smith JW, Steinhubl SR, Lincoff AM et al. Rapid platelet-function assay: An automated and quantitative cartridge-based method. Circulation 1999;99:620-625.
24. Storey RF, May JA, Wilcox RG, Heptinstall S. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: Comparison with other aggregation methodologies. Thromb Haemost 1999;82:1307-1311.
25. Neumann FJ, Hochholzer W, Pogatsa-Murray G, Schomig A, Gawaz M. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 2001;37:1323-1328.
26. Wheeler GL, Braden GA, Steinhubl SR et al. The Ultegra rapid platelet-function assay: Comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 2002;143:602-611.
27. Matzdorff AC, Kuhnel G, Kemkes-Matthes B, Voss R. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer. J Thromb Thrombolysis 2001;12:129-139.
28. Steinhubl SR, Talley JD, Braden GA et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572-2578.
29. Coleman JL WJSD. Determination of Individual response to Aspirin Therapy Using the Accumetrics Ultegra RPFA-ASA System. Point of Care 2004;2004:77-82.
30. Malinin A, Spergling M, Muhlestein B, Steinhubl S, Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004;15:295-301.
31. Aleil B, Espinosa T, Wolff V, Mossard JM, Cazenave JP, Gachet C. Evaluation of platelet responsiveness to aspirin and clopidogrel therapy: Comparison of VerifyNow, VASP and platelet aggregometry. Poster presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference, Washington DC, October 2006.
32. Dichiara J, Bliden KP, Tantry US et al. Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. Platelets 2007;18:414-423.
33. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attach and stroke: Comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005;36:1001-1005.
34. Paniccia R, Antonucci E, Gori AM et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. Am J Clin Pathol 2007;128:143-149.
35. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-1708.
36. Accumetrics Inc. RPFA-ASA (aspirin assay) package insert. San Diego, CA. 2002. (Pamphlet).
37. Accumetrics Inc. VerifyNow-ASA (aspirin assay) package insert. San Diego, CA. 2004. (Pamphlet).
38. Lee PY, Chen WH, Ng W et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005;118:723-727.
39. Wang JC, ucoin-Barry D, Manuelian D et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003;92:1492-1494.
40. Mirkhel A, Peyster E, Sundeen J et al. Frequency of aspirin resistance in a community hospital. Am J Cardiol 2006;98:577-579.
41. Batchelor WB, Tolleson TR, Huang Y et al. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: The COMPARE trial. Comparison of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 2002;106:1470-1476.
42. Accumetrics Inc. VerifyNow-P2Y12 (P2Y12 assay) package insert. San Diego, CA. 2006. (Pamphlet).
43. Malinin A, Pokov A, Spergling M et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007;119(3):277-284.
44. von Beckerath N, Pogatsa-Murray G, Wieczorek A, Sibbing D, Schomig A, Kastrati A. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 2006;95:910-911.
45. van Werkum JW, van der Stelt CA, Seesing TH, Hackeng CM, Ten Berg JM. A head-to-head comparison between the VerifyNowP2Y12-assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective PCI. J Thromb Haemost 2006;4:2516-2518.
46. Paniccia R, Antonucci E, Gori AM et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007;5:1839-1847.
47. Jakubowski JA, Payne CD, Li YG et al. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008;99:409-415.
48. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006;28:315-322.
49. FDA Enforcement Report. www.fda.gov/bbs/topics/enforce/2006/ENF00982. html. 2008. Internet Communication.
50. Price M, Valencia R, Gollapudi RR et al. The responseto clopidogrel measured by a point-of-care assay following percutaneous coronary intervention is associated with stent thrombosis over 6-month follow-up. Abstract presented at the i2 Summitt 2007, New Orleans, 2007.
51. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-1834.